Ịṅụ Oncogene

Oncogene riri ahụ  bụ usoro nke ọrịa kansa nwere mkpụrụ ndụ ihe nketa, epijenetic, ma ọ bụ kromozomal irregularities na-adabere na otu ma ọ bụ ọtụtụ mkpụrụ ndụ ihe mere eme maka nlekọta na ịdị ndụ. 'N' hi ya, mkpụrụ ndụ kansa na-adabere na mgbaàmà na-aga n'ihu site na oncogenes ndị a maka ndụ ha.  Ọ bụ dọkịta Amerịka a bụ I. Bernard Weinstein chepụtara okwu ahụ n'afọ 2002.

 Ọmụmaatụ 
Ihe atụ kachasị mma nke ọrịa kansa nke na -egosipụta ihe riri ahụ na oncogene bụ ọrịa lukemia myelogenous (CML), nke oncogene na-agbanwe agbanwe a maara dị ka Philadelphia kromozom na-akpali.  na-akpọ CML "ọrịa postter-nwatakịrị maka ịṅụ ọgwụ ọjọọ".  Ịmaatụ ndị ọzọ gụnyere gastrointestinal stromal tumor, nke nwere ike ịbụ ihe riri ahụ na mkpụrụ ndụ ihe nketa KIT; melanoma, nke nwere ikike ịbụ ihe riri ya ahụ na mkpụrụedemede BRAF; na carcinoma akpa ume na-abụghị obere mkpụrụ ndụ, nke nwere ohere ịbụ ihe riri mmadụ ahụ na mkpụrụọn ihe nketa EGFR.

E nwere ike ịgwọ ọgwụ Oncogene site n'iji ọgwụgwọ enzyme inhibitor. IhPagliarini, Raymond; Shao, Wenlin; Sellers, William R. (2015). "Oncogene addiction: Pathways of therapeutic response, resistance, and road maps toward a cure". EMBO Reports. 16 (3): 280–296. doi:10.15252/embr.201439949. PMC 4364868. PMID 25680965. atụ nke ihe mgbochi ndị e ji gbochie oncogenes ma mebie oncogene riri ahụ gụnyere imatinib, nilotinib, dasatinib, na ponatinib, n'etiti ndị ọzọ. Nagel, Remco; Semenova, Ekaterina A.; Berns, Anton (2016). "Drugging the addict: Non‐oncogene addiction as a target for cancer therapy". EMBO Reports. 17 (11): 1516–1531. doi:10.15252/embr.201643030. PMC 5090709. PMID 27702988. bụ ezie na ọgwụgwọ mbụ nwere ike inwe nsonaazụ dị mma maka ịchịkwa ọrịa kansa, ọgwụgwọ na-adịghị ala ala na-akpatakarị iguzogide ọgwụ na ịlaghachi. Mgbochi Oncogene na-akpatakarị ndụ na-enweghị ọganihu nke ọnwa ole na ole, nke pụtara na ọtụtụ ọgwụgwọ ọrịa kansa na-adabere na ọgwụgwọ kemịkal. Ihe dị ịrịba ama bụ ihe ịga nke ọma nke ọgwụgwọ inhibitorna ịgwọ CML. Usoro ọgwụgwọ inhibitor enweela ihe ịga nke ọma Amin, Amit Dipak; Rajan, Soumya S.; Groysman, Matthew J.; Pongtornpipat, Praechompoo; Schatz, Jonathan H. (2015). "Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells". Biomarkers in Cancer. 7s2 (Suppl 2): 25–32. doi:10.4137/BIC.S29326. PMC 4681422. PMID 26688666. ọrịa a, a ka na-amaghị oge ndụ na-enweghị ọganiihu, ebe ọ bụ na enwetabeghị ya n'ihe karịrị afọ iri nke nsochi azụ. 

Nghọta ndị ọzọ na-adịbeghị anya banyere mgbochi mgbochi bụ na mgbochi nke otu mkpụrụ ndụ ihe nketa nwere ike ime ka ụzọ mgbaàmà laghachi. MgbeAmin, Amit Dipak; Rajan, Soumya S.; Groysman, Matthew J.; Pongtornpipat, Praechompoo; Schatz, Jonathan H. (2015). "Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells". Biomarkers in Cancer. 7s2 (Suppl 2): 25–32. doi:10.4137/BIC.S29326. PMC 4681422. PMID 26688666. e nwere ike ịzọpụta usoro ndị na-agbadata na-egosi ma na-elekọta ọrịa kansa.